Vol. 19 No. 3 (2015)
NEUROSURGERY

CSPG4/NG2 transcriptional activity as a prognostic marker of the postoperative clinical course of glioblastoma

PDF (Русский)
  • A. Tsidulko,
  • V. Kobozev,
  • A. Volkov,
  • D. Kostromskaya,
  • S. Aidagulova,
  • R. Kiseliov,
  • T. Prudnikova,
  • A. Krivoshapkin
A. Tsidulko
Institute of Molecular Biology and Biophysics , 2/12 Timakova St., 630117 Novosibirsk, Russian Federation
Bio
V. Kobozev
Academician Ye. Meshalkin Novosibirsk Research Institute of Circulation Pathology Ministry of Health Care of Russian Federation, 15 Rechkunovskaya St., 630055 Novosibirsk, Russian Federation
Bio
A. Volkov
Academician Ye. Meshalkin Novosibirsk Research Institute of Circulation Pathology Ministry of Health Care of Russian Federation, 15 Rechkunovskaya St., 630055 Novosibirsk, Russian Federation
Bio
D. Kostromskaya
Academician Ye. Meshalkin Novosibirsk Research Institute of Circulation Pathology Ministry of Health Care of Russian Federation, 15 Rechkunovskaya St., 630055 Novosibirsk, Russian Federation
Bio
S. Aidagulova
Novosibirsk State Medical University Ministry of Health Care of Russian Federation, 52 Krasniy Prospect, 630091 Novosibirsk, Russian Federation
Bio
R. Kiseliov
Novosibirsk State Medical University Ministry of Health Care of Russian Federation, 52 Krasniy Prospect, 630091 Novosibirsk, Russian Federation
Bio
T. Prudnikova
Institute of Molecular Biology and Biophysics , 2/12 Timakova St., 630117 Novosibirsk, Russian Federation
Bio
A. Krivoshapkin
Academician Ye. Meshalkin Novosibirsk Research Institute of Circulation Pathology Ministry of Health Care of Russian Federation, 15 Rechkunovskaya St., 630055 Novosibirsk, Russian Federation; European Medical Center, 35 Schepkina St., 129090 Moscow, Russian Federation
Bio
DOI: https://doi.org/10.21688/1681-3472-2015-3-110-113

Published 2015-10-27

Keywords

  • glioblastoma,
  • CSPG4/NG2 gene,
  • chondroitin sulfate proteoglycan,
  • prognosis

How to Cite

Tsidulko, A., Kobozev, V., Volkov, A., Kostromskaya, D., Aidagulova, S., Kiseliov, R., Prudnikova, T., & Krivoshapkin, A. (2015). CSPG4/NG2 transcriptional activity as a prognostic marker of the postoperative clinical course of glioblastoma. Patologiya Krovoobrashcheniya I Kardiokhirurgiya, 19(3), 110–113. https://doi.org/10.21688/1681-3472-2015-3-110-113

Copyright (c) 2015 Tsidulko A.Yu., Kobozev V.V., Volkov A.M., Kostromskaya D.V., Aidagulova S.V., Kiseliov R.S., Prudnikova T.Yu., Krivoshapkin A.L.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Objective. Glioblastoma is a malignant brain tumor characterized by severe invasive growth and poor prognosis. The expression of different genes is changed in tumors, including gene CSPG4/NG2, which plays a significant role in the proliferation of glioblastoma cells and tumor neovascularization. The objective of our study was to evaluate the possibility of using the above gene as a prognostic marker for glioblastoma.
Methods. 8 patients with a diagnosis "glioblastoma" underwent clinical and molecular-biological examination. The tumor samples were fixed in RNA-later (LifeTechnologies, USA). CSPG4/NG2 and CD44 expression was evaluated by real-time RT-PCR with GAPDH as a reference gene. The patients were divided into two groups according to the postoperative survival rate: Group 1 – less than 1 year, and Group 2 – over 1 year after surgery.
Results. Molecular biological studies showed a significant 4-fold increase of CSPG4/NG2 expression level in tumors from group 1 as compared to that of group 2 patients. It was also found out that increased CSPG4/NG2 expression in galloping tumors is in positive correlation with an increase in cancer stem-cell marker CD44 expression (Pearson coefficient 0.9514).
Conclusion. The data obtained suggest that CSPG4/NG2 is a promising prognostic marker to determine optimal postoperative treatment of patients with glioblastoma.

PDF (Русский)

References

  1. Гайтан А.С., Кривошапкин А.Л., Каныгин В.В. Результаты резекции глиобластом головного мозга с применением комбинированной флуоресцентной навигации // Патология кровообращения и кардиохирургия. 2014. Т. 2. С. 37–41.
  2. Chekenya M., Krakstad C., Svendsen A. et al. // Oncogene. 2008. Vol. 27. № 39. P. 5182–5194.
  3. Hsu N.C., Nien P.Y., Yokoyama K.K. et al. // Biochem. Biophys. Res. Commun. 2013. Vol. 441. № 2. P. 514–518.
  4. Karsy M., Neil J.A., Guan J. et al. // Neurosurg. Focus. 2015. Vol. 38. № 3. P. E4. doi: 10.3171/2015.1.FOCUS14755.
  5. Petrovici K., Graf M., Hecht K. et al. // Cancer Genomics Proteomics. 2010. Vol. 7. № 4. P. 173–180.
  6. Pointer K.B., Clark P.A., Zorniak M. et al. // Neurochem. Int. 2014. Vol. 71. P. 1–7.
  7. Price M.A., Colvin Wanshura L.E., Yang J. et al. // Pigment Cell Melanoma Res. 2011. Vol. 24. № 6. P. 1148–1157.
  8. Stallcup W.B., Huang F-J. // Cell Adh. Migr. 2008. Vol. 2. № 3. P. 192–201.
  9. Svendsen A., Verhoeff J.J., Immervoll H. et al. // Acta Neuropathol. 2011. Vol. 122. № 4. P. 495–510.
  10. Wang J., Svendsen A., Kmiecik J. et al. // PLoS One. 2011. Vol. 6. № 7. P. e23062. doi:10.1371/journal.pone.0023062